Physiologic Insights from the COPD Genetic Epidemiology Study
- PMID: 31342731
- PMCID: PMC6872216
- DOI: 10.15326/jcopdf.6.3.2019.0128
Physiologic Insights from the COPD Genetic Epidemiology Study
Abstract
COPD Genetic Epidemiology Study (COPDGene®) manuscripts have provided important insights into chronic obstructive pulmonary disease (COPD) pathophysiology and outcomes, including a better understanding of COPD phenotypes relating computed tomography (CT) anatomic data to spirometric and patient-reported outcomes. Spirometry significantly underdiagnoses smoking-induced lung disease, and there is a marked improvement in sensitivity and specificity with CT scanning. This review also highlights the COPDGene® exploration of specific spirometry phenotypes (e.g.,PRISm), contributors to spirometric decline, composite physiologic measures, asthma-COPD overlap (ACO) syndrome, consequences of bronchodilator responsiveness, newer methods to assess small airway dysfunction, and spirometric correlates of comorbid diseases such as obesity and diabetes.
Keywords: COPD Genetic Epidemiology; COPDGene; PRISm; Preserved Ratio Impaired Spirometry; asthma-COPD overlap; chronic obstructive pulmonary disease; copd.
JCOPDF © 2019.
Conflict of interest statement
WWS reports research grants from Boehringer Ingelheim, AstraZeneca, Astellas and consulting with Allergan and Syneos Health. SPB has received research grants from the National Institutes of Health (K23HL133438) and from ProterixBio. He has served on advisory boards for Sunovion and GlaxoSmithKline. MCM reports royalties for authorship from UpToDate and consulting with GlaxoSmithKline. BJM reports consulting agreements and/or grant funding and/or advisory board service for AstraZeneca, the National Heart Lung and Blood Institute, Spiration, GlaxoSmithKline, Sunovion, Pearl, Verona, Boehringer Ingelheim, Theravance, Circassia, Third Pole, Shire, and Phillips. RC reports research grants from Boehringer Ingelheim, Astra Zeneca, Astellas, Glaxo SmithKline; service on advisory boards from Boehringer Ingelheim, GlaxoSmithKline; consulting for Regeneron, Genetech; speakers bureau for Boehringer Ingelheim, Astra Zeneca and GlaxoSmithKline. JP has nothing to declare.
References
-
- Regan EA,Hokanson JE,Murphy JR,et al.Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7(1):32-43. doi: https://doi.org/10.3109/15412550903499522 - PMC - PubMed
-
- Lundbäck B,Backman H,Calverley PMA.Lung Function through the PRISm: spreading light or creating confusion?. Am J Respir Crit Care Med. 2018;198(11):1358-1360. doi: https://doi.org/10.1164/rccm.201806-1163ED - PubMed
-
- Sood A,Petersen H,Qualls C,et al.Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. Respir Res. 2016;17(1):147. doi: https://doi.org/10/1186/s/12931-016-0468-7 - PMC - PubMed
-
- Fortis S,Eberlein M,Georgopoulos D,Comellas AP.Predictive value of prebronchodilator and postbronchodilator spirometry for COPD features and outcomes. BMJ Open Respir Res. 2017;4(1):e000213. doi: https://doi.org/10.1136/bmjresp-2017-000213 - PMC - PubMed
-
- Chevalier-Bidaud B,Gillet-Juvin K,Callens E,et al.Non-specific pattern of lung function in a respiratory physiology unit: causes and prevalence: results of an observational cross-sectional and longitudinal study. BMC Pulm Med. 2014;14:148. doi: https://doi.org/10.1186/1471-2466-14-148 - PMC - PubMed